Abstract
Non-functioning pituitary adenomas (NFPAs) comprise silent tumors of different pituitary lineages that tend to escape early detection and present as invasive macroadenomas with symptoms of mass effect. Incomplete surgical resection is common and may be followed by significant rates of subsequent remnant progression. Pituitary tumors are defined as refractory when resistance to optimal standard therapies including surgery, radiotherapy, and medical treatment is documented. In the absence of approved medications for the treatment of NFPAs, the last criterion to classify these tumors as refractory is ill defined. Silent corticotroph and null cell adenomas have been reported, albeit not in all studies, to be larger and recur more often compared with silent gonadotroph tumors. Nevertheless, it is currently unknown if certain NFPA subtypes are more often refractory using well defined criteria. The response rate to temozolomide is lower in NFPA compared to that seen in functioning tumors. Refractory NFPAs present a significant diagnostic and therapeutic challenge and are associated with increased morbidity and mortality rates.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The authors confirm that all supportive data are available within the article.
References
Chen Y et al (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4):333–342
McCormack A et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a european Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265–276
Botelho MS et al (2022) Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis. Pituitary 25(6):810–818
Greenman Y et al (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175(1):63–72
Chanson P, Dormoy A, Dekkers OM (2019) Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol 181(1):D1–D13
Dekkers OM, Karavitaki N, Pereira AM (2020) The epidemiology of aggressive pituitary tumors (and its challenges). Rev Endocr Metab Disord 21(2):209–212
Burman P et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593–605
Asa SL et al (2022) Overview of the 2022 WHO classification of Pituitary Tumors. Endocr Pathol 33(1):6–26
Drummond J et al (2019) Clinical and pathological aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab 104(7):2473–2489
Chatrath A et al (2022) Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications. Pituitary 25(6):988–996
Haddad AF et al (2020) Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. Neurosurg Focus 48(6):E13
Cohen-Inbar O et al (2017) Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study. J Neurooncol 135(1):67–74
Raverot G et al (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17(11):671–684
Zheng G et al (2020) Clinical, Laboratory, and treatment profiles of Silent Corticotroph Adenomas that have transformed to the functional type: a Case Series with a literature review. Front Endocrinol (Lausanne) 11:558593
Portovedo S et al (2022) Aggressive nonfunctioning pituitary neuroendocrine tumors. Brain Tumor Pathol 39(4):183–199
Funding
No funding.
Author information
Authors and Affiliations
Contributions
The first draft of the manuscript was written by TK and YG. Both authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval
Not applicable.
Competing interests
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kolitz, T., Greenman, Y. Refractory nonfunctioning pituitary adenomas. Pituitary 26, 278–280 (2023). https://doi.org/10.1007/s11102-023-01298-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-023-01298-4